<DOC>
	<DOCNO>NCT01086280</DOCNO>
	<brief_summary>The purpose study compare incidence major cardiovascular event among patient type 2 diabetes new initiator Saxagliptin new initiator oral anti-diabetic drug ( OADs ) class Dipeptidyl peptidase IV ( DPP4 ) inhibitor .</brief_summary>
	<brief_title>Risk Cardiovascular Events Patients With Type 2 Diabetes Initiating Oral Antidiabetic Treatments</brief_title>
	<detailed_description>Prospectively design retrospective database study . This study conduct use administrative claim data electronic medical record collect part routine clinical practice</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>18 year age old Newly prescribe Saxagliptin OAD class DPP4 inhibitor Enrolled respective database least 180 day prior first prescription Saxagliptin OAD class DPP4 inhibitor Patients identify diagnostic code cardiovascular outcome interest within 180day baseline period Patients prescribed DPP4 inhibitor baseline period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>